IGM Biosciences, Inc. Quarterly Operating Income (Loss) in USD from Q1 2018 to Q2 2024

Taxonomy & unit
us-gaap: USD
Description
The net result for the period of deducting operating expenses from operating revenues.
Summary
IGM Biosciences, Inc. quarterly/annual Operating Income (Loss) history and growth rate from Q1 2018 to Q2 2024.
  • IGM Biosciences, Inc. Operating Income (Loss) for the quarter ending June 30, 2024 was -$51.4M, a 24.7% increase year-over-year.
  • IGM Biosciences, Inc. Operating Income (Loss) for the twelve months ending June 30, 2024 was -$237M, a 4.54% increase year-over-year.
  • IGM Biosciences, Inc. annual Operating Income (Loss) for 2023 was -$263M, a 15.6% decline from 2022.
  • IGM Biosciences, Inc. annual Operating Income (Loss) for 2022 was -$228M, a 37.9% decline from 2021.
  • IGM Biosciences, Inc. annual Operating Income (Loss) for 2021 was -$165M, a 98.5% decline from 2020.
Operating Income (Loss), Trailing 12 Months (USD)
Operating Income (Loss), Quarterly (USD)
Operating Income (Loss), YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q2 2024 -$237M -$51.4M +$16.9M +24.7% Apr 1, 2024 Jun 30, 2024 10-Q 2024-08-14
Q1 2024 -$254M -$53.9M +$9.52M +15% Jan 1, 2024 Mar 31, 2024 10-Q 2024-05-08
Q4 2023 -$263M -$65.1M -$8.86M -15.7% Oct 1, 2023 Dec 31, 2023 10-K 2024-03-07
Q3 2023 -$255M -$66.8M -$6.25M -10.3% Jul 1, 2023 Sep 30, 2023 10-Q 2023-11-13
Q2 2023 -$248M -$68.2M -$8.98M -15.2% Apr 1, 2023 Jun 30, 2023 10-Q 2024-08-14
Q1 2023 -$239M -$63.4M -$11.4M -22% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-08
Q4 2022 -$228M -$56.3M -$5.58M -11% Oct 1, 2022 Dec 31, 2022 10-K 2024-03-07
Q3 2022 -$222M -$60.5M -$16.3M -36.9% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-13
Q2 2022 -$206M -$59.2M -$20.5M -52.9% Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-03
Q1 2022 -$186M -$52M -$20.3M -63.9% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-12
Q4 2021 -$165M -$50.7M -$25.9M -105% Oct 1, 2021 Dec 31, 2021 10-K 2024-03-07
Q3 2021 -$139M -$44.2M -$23.6M -115% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-03
Q2 2021 -$116M -$38.7M -$19.3M -99.6% Apr 1, 2021 Jun 30, 2021 10-Q 2022-08-08
Q1 2021 -$96.4M -$31.7M -$13.1M -70.7% Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-09
Q4 2020 -$83.3M -$24.7M -$8.8M -55.2% Oct 1, 2020 Dec 31, 2020 10-K 2021-03-30
Q3 2020 -$74.5M -$20.6M -$9.89M -92.6% Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-04
Q2 2020 -$64.6M -$19.4M -$8.88M -84.3% Apr 1, 2020 Jun 30, 2020 10-Q 2021-08-09
Q1 2020 -$55.7M -$18.6M -$11.2M -152% Jan 1, 2020 Mar 31, 2020 10-Q 2021-05-06
Q4 2019 -$44.5M -$15.9M -$6.89M -76.2% Oct 1, 2019 Dec 31, 2019 10-K 2021-03-30
Q3 2019 -$37.6M -$10.7M -$4.13M -63.1% Jul 1, 2019 Sep 30, 2019 10-K 2021-03-30
Q2 2019 -$33.5M -$10.5M -$6.29M -148% Apr 1, 2019 Jun 30, 2019 10-K 2021-03-30
Q1 2019 -$27.2M -$7.36M -$4.4M -149% Jan 1, 2019 Mar 31, 2019 10-K 2021-03-30
Q4 2018 -$22.8M -$9.05M Oct 1, 2018 Dec 31, 2018 10-K 2020-03-26
Q3 2018 -$6.55M Jul 1, 2018 Sep 30, 2018 10-K 2020-03-26
Q2 2018 -$4.24M Apr 1, 2018 Jun 30, 2018 10-K 2020-03-26
Q1 2018 -$2.96M Jan 1, 2018 Mar 31, 2018 10-K 2020-03-26
* An asterisk sign (*) next to the value indicates that the value is likely invalid.